Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary
Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Product Name : Arixtra
Product Type : Miscellaneous
Upfront Cash : $310.4 million
September 08, 2020
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : HAEMONETICS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arixtra is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2013
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : HAEMONETICS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Fondaparinux in Critically Ill Patients With Renal Failure
Details : Fondaparinux is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thromboembolism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2011
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Details : Fondaparinux Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2010
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
